A practical reference on CAS Registry Number: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-30 and is reviewed periodically as new material appears.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
==== Application ==== Some of the applications of these CSPs include the direct chiral analysis of β-adrenergic blockers such as metoprolol and celiprolol, the calcium channel blocker, felodipine and the anticonvulsant agent, ethotoin.
To reduce radiation exposure, the American Society of Nuclear Cardiology (ASNC) issued dosage recommendations in 2010. The effective dose is 2.4 mSv for 13N-ammonia, 2.5 mSv for 15O-water, 7 mSv for 18F-fluorodeoxyglucose, and 13.5 mSv for 82Rb-rubidium chloride. Compliance with these recommendations is expected to reduce the average radiation exposure to = 9 mSv. The Ordinance on Radioactive Drugs or Drugs Treated with Ionizing Radiation § 2 AMRadV (in German) regulates the approval procedures for the marketability of radioactive drugs.
One month later, HVEC announced it was mothballing the XTU and closing the Van de Graaff Research Laboratory in Burlington. The market failure of the XTU coincided with new competitive pressures. Operational difficulties with HVEC's Emperor tandems further damaged the company's competitive position. Laboratories reported technical problems with the Emperor requiring costly component replacements. In 1965, fellow physicist and former HVEC consultant Ray Herb founded the National Electrostatics Corporation. The company's durable Pelletron charging technology became the favored platform for federally-funded accelerator research. HVEC sold its final two Emperor models to French national laboratories in 1973.
=== Air freight === South Africa's air freight sector serves primarily international trade rather than domestic distribution. Most air freight consists of high-value, perishable, and/or time-sensitive goods that cannot economically be transported by sea or road. Air freight represents well under 1% of South Africa's freight by mass, but carries a disproportionately high share of high-value goods. The country's air cargo network is dominated by O.R. Tambo International Airport in Johannesburg, which functions as Southern Africa's principal air cargo gateway. The airport has a total cargo capacity of 650,000 tons. According to the Department of Transport's Draft Airfreight Strategy for South Africa, 2025, by weight, 95% of all air freight flows through O.R. Tambo, with a further 3% transiting via Cape Town International, and 1% via King Shaka International. The same draft identified O.R. Tambo International and Cape Town International as the country's principal air cargo gateways. Domestic air freight accounts for less than 5% of total air freight in SA. South Africa's air freight market size was estimated at approximately R55.3 billion in 2024, with a projected CAGR of 8.75% through 2030. Also in 2024, South Africa accounted for a 19.5% share of the total air freight market in the Middle East and Africa region. The majority state-owned Airports Company South Africa (ACSA) manages all of South Africa's largest airports by cargo volume. The three largest such airports are O.R.
Sources: en.wikipedia.org
premature cardiovascular disease Familial hypercholesterolaemia family history of premature cardiovascular disease family history of elevated Lp(a) recurrent cardiovascular disease despite statin treatment ≥3% ten-year risk of fatal cardiovascular disease according to the European guidelines ≥10% ten-year risk of fatal and/or non-fatal cardiovascular disease according to the U.S. guidelines If the level is elevated, treatment should be initiated to bring the level below 50 mg/dL. In addition, the patient's other cardiovascular risk factors (including LDL levels) should be managed optimally. Apart from the total Lp(a) plasma concentration, the apo(a) isoform might be an important risk parameter as well. Prior studies of the relationship between Lp(a) and ethnicity have shown inconsistent results. Lp(a) levels seem to differ in different populations. For example, in some African populations, Lp(a) levels are higher on average than in other groups, so that using a risk threshold of 30 mg/dl could classify over 50% of the individuals as higher risk. Some part of this complexity may be related to the different genetic factors involved in determining Lp(a) levels. One recent study showed that in different ethnic groups, different genetic alterations were associated with increased Lp(a) levels. More recent data suggest that prior studies were underpowered. The Atherosclerosis Risk in Communities (ARIC) Study followed 3467 African Americans and 9851 whites for 20 years. The researchers found that an elevated Lp(a) conferred the same risk in each group.
== Techniques == Techniques commonly used in the field of phytochemistry are extraction, isolation, and structural elucidation (MS,1D and 2D NMR) of natural products, as well as various chromatography techniques (MPLC, HPLC, and LC-MS).
== External links == Calvete JJ (1995). "On the structure and function of platelet integrin alpha IIb beta 3, the fibrinogen receptor". Proc. Soc. Exp. Biol. Med. 208 (4): 346–60. doi:10.3181/00379727-208-43863a. PMID 7535429. Garner Stephen F., Campbell Kate, Metcalfe Paul, Keidan Jane, Huiskes Elly, Dong Jing-Fei, Lopez Jose A., Ouwehand Willem H. (2002). "Glycoprotein V: the predominant target antigen in gold-induced autoimmune thrombocytopenia" (PDF). Blood. 100 (1): 344–346. doi:10.1182/blood.V100.1.344. PMID 12070047.{{cite journal}}: CS1 maint: multiple names: authors list (link) Dumin J A, Dickeson S K, Stricker T P, Bhattacharyya-Pakrasi M, Roby J D, Santoro S A, Parks W C (2001). "Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen". J. Biol. Chem. 276 (31): 29368–74. doi:10.1074/jbc.M104179200. PMID 11359786.{{cite journal}}: CS1 maint: multiple names: authors list (link) http://www.reference.md/files/D019/mD019038.html Online Medical Dictionary, Platelet membrane glycoproteins Platelet+membrane+glycoproteins at the U.S. National Library of Medicine Medical Subject Headings (MeSH) http://www.ojrd.com/content/1/1/46/figure/F1?highres=y http://circ.ahajournals.org/content/99/1/e1/F4.large.jpg
== Adverse effects == There is a need for controlled clinical trials before the safety of ibogaine can be established; existing evidence, largely from uncontrolled case reports, links it to significant acute and long-term adverse events (especially cardiac issues like QTc prolongation), including fatalities. It should only be used in medically supervised settings with thorough screening and continuous cardiac and psychiatric monitoring. Ibogaine can cause various cardiovascular changes (e.g., slowed heart rate, blood pressure shifts), neurological effects (ataxia, tremor, mania), and rare but serious complications, including arrhythmias, respiratory failure, and death, especially when combined with opioids or in patients with underlying conditions. Cardiac risks likely occur through hERG channel blockade leading to QT prolongation and arrhythmias; the synthetic analog 18-MC appears to produce much less of this dangerous effect despite similar binding affinity. A 2022 review found 58 ibogaine-associated emergencies, including 38 deaths. Two of these deaths occurred in the setting of clinical studies. According to a 2012 estimate, 1 in every 300 patients who take ibogaine die.
=== Pasteurized donkey milk === Donkey milk is pasteurized in a closed circuit of pasteurization and bottling (aseptic) at least 72 °C for 15 seconds or equivalent times and temperatures. In the case of pasteurization in discontinuous systems, the temperature must be higher depending on the method used and the type of plant and destination.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.